Since the First-in-Human milestonein July, 2023, we have meticulously evaluated the safety profile and pharmacological dose of APS03118. This rigorous investigation has revealed the notable potential efficacy of this novel next-generation RET inhibitor in a study population with advanced RET-altered non-small cell lung cancer and late-stage medullary thyroid carcinoma. We extend our profound gratitude to all patients and investigators involved in the preliminary clinical trials; their invaluable contributions are the foundation of our progress in this research.Currently, we are methodically advancing the preparatory phase for the pivotal clinical trials. Our objectives are twofold: to confirm the therapeutic efficacy of APS03118 within the established realms of study and to explore its application in additional RET-altered solid tumors. In pursuit of these goals, we are actively engaging in strategic collaborations with leading cancer centers across China，EU and US, aiming to achieve more significant research outcomes in the future.